Early drug discovery depends on connecting diverse scientific insights into a coherent view. Yet, biological and chemical data are often separated across systems, limiting shared understanding.
These gaps reduce clarity, slow collaboration, and hinder timely, evidence-based decisions.
Data integration addresses these challenges by aligning information across disciplines. This white paper explores the:
- Challenges caused by fragmented data
- Advantages of unified data for cross-functional workflows
- Barriers to integrating and standardising discovery data
- Unified data connects targets, compounds, pathways, and pharmacological evidence to guide decisions.
CAS, a global curator and connector of data sources, provides an integrated platform that unifies biological and chemical data: the CAS BioFinder. This helps discovery teams strengthen decision-making, reduce downstream risk, and accelerate early drug discovery outcomes.
